Navigation Links
Complete Genomics and Illumina Settle Patent Litigation
Date:7/18/2013

MOUNTAIN VIEW, Calif., July 18, 2013 /PRNewswire/ -- Complete Genomics, Inc. (formerly NASDAQ: GNOM) ("Complete"), a wholly-owned subsidiary of BGI-Shenzhen ("BGI"), a leading international genomics organization based in Shenzhen, China, today announced that it has entered into a settlement agreement with Illumina, Inc. under which Illumina will dismiss with prejudice both lawsuits it had brought against Complete:  Illumina, Inc. and Solexa, Inc. v. Complete Genomics, Inc., Case No. 10-cv-05542 EDL (N.D. Cal.); and Illumina, Inc. and Illumina Cambridge Ltd. v. Complete Genomics, Inc., Case No. 12-cv-01465 BEN BGS (S.D. Cal).  Complete will dismiss with prejudice all counterclaims.  The parties have entered into mutual releases, and each party will bear its own litigation costs.  No payment is being made by either party to the other, and no licenses are being granted by either party to the other.

"We are pleased to have reached a settlement with Illumina regarding this matter.  This resolution allows Complete to focus on its vision of revolutionizing medicine through the use of whole genome sequencing," Dr. Clifford Reid, CEO of Complete, said.

About Complete

Complete Genomics provides the most accurate whole human genome sequencing available today. The company's proprietary sequencing technology and advanced informatics and analysis software provide researchers and clinicians worldwide with the genomic information needed to better understand the prevention, diagnosis, and treatment of diseases. Additional information can be found at http://www.completegenomics.com.


'/>"/>
SOURCE Complete Genomics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Complete Titrator Systems from Cole-Parmer Offer Easy-To-Use Apps-Based Interface
2. Replicel and Shiseido Complete Collaboration and Technology Transfer Agreement on Technology for Treating Pattern Baldness
3. Eurofins MWG Operon Quality Assurance Group Completes ISO Certifications for Their New Overnight Sequencing Lab
4. Oligomerix, Inc. Completes Series B Financing
5. Leviticus Cardio Ltd. Completes a Successful Animal Trial for its Wireless Energy System for VADs
6. St. Mary Completes Phase 2 of Its Emergency Department and Trauma Center Expansion
7. Centene Corporation Completes Acquisition Of Specialty Pharmacy Leader AcariaHealth
8. bioRASI Completes Acquisition of Ukrainian CRO
9. Novira Therapeutics Completes $25 Million Series A Financing
10. SoundMindz TM Releases ‘Anti-Anxiety TM’ Mobile App - A Complete Stress Therapy Program
11. BGI-Shenzhen Completes Acquisition of Complete Genomics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... Iowa (PRWEB) , ... October 12, 2017 , ... ... based in Vilnius, Lithuania, announced today that they have entered into a multiyear ... is to provide CRISPR researchers with additional tools for gene editing across all ...
(Date:10/12/2017)... ... 2017 , ... AMRI, a global contract research, development and ... outcomes and quality of life, will now be offering its impurity solutions as ... regulatory requirements for all new drug products, including the finalization of ICH M7 ...
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 system ... experiments and avoiding the use of exogenous expression plasmids. The simplicity of programming ... systematic gain-of-function studies. , This complement to loss-of-function studies, such as with ...
(Date:10/11/2017)... ... 11, 2017 , ... Proscia Inc ., a data ... titled, “Pathology is going digital. Is your lab ready?” with Dr. Nicolas Cacciabeve, ... and how Proscia improves lab economics and realizes an increase in diagnostic confidence.* ...
Breaking Biology Technology:
(Date:4/5/2017)... SEATTLE , April 5, 2017  The Allen ... the Allen Cell Explorer: a one-of-a-kind portal and dynamic ... large-scale 3D imaging data, the first application of deep ... edited human stem cell lines and a growing suite ... the platform for these and future publicly available resources ...
(Date:4/5/2017)... 2017 KEY FINDINGS The global ... a CAGR of 25.76% during the forecast period of ... factor for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is ... geography. The stem cell market of the product is ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
Breaking Biology News(10 mins):